US House committee report challenges FDA approval of Alzheimer's drug
The US House Committees on Oversight and Reform & Energy and Commerce Thursday jointly released a report criticizing the US Food and Drug Administration’s (FDA) approval of Alzheimer’s drug Aduhelm. The report says that the FDA and Aduhelm-manufacturer Biogen acted in concert to get the drug approved in a hastened manner despite doubts about Aduhelm’s [...]